Simple Summary Pancreatic ductal adenocarcinoma (PDAC) has a high mortality rate and a
poor prognosis. To solve the above limitations of multiomics studies of metabolism in PDAC …

Currently, approximately 95% of pancreatic cancers are pancreatic ductal adenocarcinomas
(PDAC), which are the most aggressive form and the fourth leading cause of cancer death …

Introduction The aim of present study was to profile the glucose-dependent and glutamine-
dependent metabolism in pancreatic cancer. Methods We performed Immunohistochemical …

We provide a comprehensive review of the analytical technologies applied in pancreatic
cancer (PC) research, investigating tumor-associated metabolites identified as possible new …

Molecular profiling of primary tumors may facilitate the classification of patients with cancer
into more homogenous biological groups to aid clinical management. Metabolomic profiling …

Pancreatic ductal adenocarcinoma is one of the most lethal tumors since it is usually
detected at an advanced stage in which surgery and/or current chemotherapy have limited …

Although targeting cancer metabolism is a promising therapeutic strategy, clinical success
will depend on an accurate diagnostic identification of tumor subtypes with specific …

Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers. Developing
biomarkers for early detection and chemotherapeutic response prediction is crucial to …

Our study aimed to identify a urinary metabolite panel for the detection/diagnosis of
pancreatic ductal adenocarcinoma (PDAC). PDAC continues to have poor survival …

Although several altered metabolic genes have been identified to be involved in the
tumorigenesis and advance of pancreatic cancer (PC), their prognostic values remained …